Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabigerol (CBG) is a non-psychoactive cannabinoid and a minor constituent of the cannabis plant. It is the decarboxylated form of cannabigerolic acid (CBGA), which serves as the precursor molecule for other major cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). CBG acts as a weak partial agonist at cannabinoid CB1 and CB2 receptors but has much higher potency as an agonist at alpha-2 adrenergic receptors, an antagonist at serotonin 5-HT1A receptors, and an antagonist at transient receptor potential channel TRPM8. These diverse mechanisms contribute to its pharmacological profile, including potential anti-inflammatory, analgesic, anxiolytic, hypotensive, antioxidant effects, and possible applications in metabolic syndrome and cardiovascular diseases. Recent clinical research suggests that oral administration of CBG can reduce anxiety without causing intoxication[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabigerol.